Red clover extract: A putative source for simultaneous treatment of menopausal disorders and the metabolic syndrome

Menopause

Volumn 15, Issue 6, 2008, Pages 1120-1131

  Mueller, Monika ^a   Jungbauer, Alois ^a,b  

^a UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

^b NONE   (Austria)

Author keywords

Diabetes.; Isoflavones; Metabolic syndrome; Peroxisome proliferators activated receptor; Red clover; Trifolium pratense

Indexed keywords

3' HYDROXYGENISTEIN; 4 ETHYLPHENOL; 6 HYDROXYDAIDZEIN; 6' HYDROXY O DESMETHYLANGOLENSIN; ALSIDIABET; ANGOLENSIN; BIOCHANIN A; DAIDZEIN; DAIDZIN; DIABETRUW; DIHYDROBIOCHANIN A; DIHYDRODAIDZEIN; DIHYDROFORMONONETIN; DIHYDROGENISTEIN; EQUOL; FORMONONETIN; GENISTEIN; GENISTIN; GLUKOKINE; HERBACEOUS AGENT; ISOFLAVONE DERIVATIVE; O DESMETHYLANGOLENSIN; ONONIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PRUNETIN; RED CLOVER EXTRACT; ROSIGLITAZONE; SISSOTRIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZIMT PLUS; GLYCOSIDE; PLANT EXTRACT;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BINDING; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ELECTROSPRAY MASS SPECTROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HORMONAL THERAPY; MENOPAUSAL SYNDROME; METABOLIC SYNDROME X; MOUSE; NONHUMAN; RED CLOVER; TRANSACTIVATION; CLOVER; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; HOT FLUSH; HUMAN; MENOPAUSE; METABOLISM;

DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCOSIDES; HOT FLASHES; HUMANS; ISOFLAVONES; MENOPAUSE; METABOLIC SYNDROME X; PLANT EXTRACTS; PPAR GAMMA; TRIFOLIUM;

EID: 63349083937     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e31817062ce     Document Type: Article

References (52)

1. Beck V, Rohr U, Jungbauer A. Phytoestrogens derived from red clover: an alternative to estrogen replacement therapy? J Steroid Biochem Mol Biol 2005;94:499-518.
2. Mourits MJE, De Bock GH. Exogenous steroids for menopausal symptoms and breast/endometrial cancer risk. Int Gynecol Cancer 2006;16:494-496.
3. Bernstein L. The risk of breast, endometrial and ovarian cancer in users of hormonal preparations. Basic Clin Pharmacol Toxicol 2006;98:288-296.
4. Fernandez E, Gallus S, Bosetti C, Franceschi S, Negri E, La Vecchia C. Hormone replacement therapy and cancer risk: a systematic analysis from a network of case-control studies. Int J Cancer 2003;105:408-412.
5. Kuiper GGJM, Lemmen JG, Carlsson B, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor? Endocrinology 1998;139:4252-4263.
6. Morito K, Aomori T, Hirose T, et al. Interaction of phytoestrogens with estrogen receptors α and β (II). Biol Pharmacol Bull 2002;25:48-52.
7. Dornstauder E, Jisa E, Unterrieder I, Krenn L, Kubelka W, Jungbauer A. Estrogenic activity of two standardized red clover extracts (Menoflavon®) intended for large scale use in hormone replacement therapy. J Steroid Biochem Mol Biol 2001;78:67-75.
8. Kinjo J, Tsuchihashi R, Morito K, et al. Interactions of phytoestrogens with estrogen receptors α and β (III). Estrogenic activities of soy isoflavone aglycones and their metabolites isolated from human urine. Biol Pharmacol Bull 2004;27:185-188.
9. Setchell KDR, Cassidy A. Dietary isoflavones: biological effects and relevance to human health. J Nutr 1999;129:758S-767S.
10. Geller S, Studee L. Soy and red clover for mid-life and aging. Climacteric 2006;9:245-263.
11. Hidalgo LA, Chedraui PA, Morocho N, Ross S, San Miguel G. The effect of red clover isoflavones on menopausal symptoms, lipids and vaginal cytology in menopausal women: a randomized, double-blind, placebo-controlled study. Gynecol Endocrinol 2005;21:257-264.
12. Van De Weijer PHM, Barentsen R. Isoflavones from red clover (Promensil®) significantly reduce menopausal hot flush symptoms compared with placebo. Maturitas 2002;42:187-193.
13. Lukaczer D, Darland G, Tripp M, et al. Clinical effects of a proprietary combination isoflavone nutritional supplement in menopausal women: a pilot trial. Altern Ther Health Med 2005;11:60-65.
14. Chedraui P, Hidalgo L, San Miguel G, Morocho N, Ross S. Red clover extract (MF11RCE) supplementation and postmenopausal vaginal and sexual health. Int J Gynecol Obstet 2006;95:296-297.
15. Imhof M, Gocan A, Reithmayr F, et al. Effects of a red clover extract (MF11RCE) on endometrium and sex hormones in postmenopausal women. Maturitas 2006;55:76-81.
16. Knudson Schult TM, Ensrud KE, Blackwell T, Ettinger B, Wallace R, Tice JA. Effect of isoflavones on lipids and bone turnover markers in menopausal women. Maturitas 2004;48:209-218.
17. Asgary S, Moshtaghian J, Naderi G, et al. Effects of dietary red clover on blood factors and cardiovascular fatty streak formation in hypercholesterolemic rabbits. Phytother Res 2007;21:768-770.
18. Nestel PJ, Pomeroy S, Sally K, et al. Isoflavones from red clover improve systemic arterial compliance but not plasma lipids in menopausal women. J Clin Endocrinol Metab 1999;84:895-898.
19. Tsvetkov K, Petkova U. Menoflavon and lipid profile in menopausal women. Akush Ginekol 2005;44(Suppl 2):3-6.
20. Lee J-S. Effects of soy protein and genistein on blood glucose, antioxidant enzyme activities, and lipid profile in streptozotocin-induced diabetic rats. Life Sci 2006;79:1578-1584.
21. Mezei O, Banz WJ, Steger RW, Peluso MR, Winters TA, Shay N. Soy isoflavones exert antidiabetic and hypolipidemic effects through the PPAR pathways in obese Zucker rats and murine RAW 264.7 cells. J Nutr 2003;133:1238-1243.
22. Cheng SY, Shaw NS, Tsai KS, Chen CY. The hypoglycemic effects of soy isoflavones on postmenopausal women. J Womens Health 2004;13:1080-1086.
23. Ae Park S, Choi M-S, Cho S-Y, et al. Genistein and daidzein modulate hepatic glucose and lipid regulating enzyme activities in C57BL/KsJ-db/db mice. Life Sci 2006;79:1207-1213.
24. Howes JB, Tran D, Brillante D, Howes LG. Effects of dietary supplementation with isoflavones from red clover on ambulatory blood pressure and endothelial function in postmenopausal type 2 diabetes. Diabetes Obes Metab 2003;5:325-332.
25. Chan YH, Lau KK, Yiu KH, et al. Isoflavone intake in persons at high risk of cardiovascular events: implications for vascular endothelial function and the carotid atherosclerotic burden. Am J Clin Nutr 2007;86:938-945.
26. Vedavanam K, Srijayanta S, O'Reilly J, Raman A, Wiseman H. Antioxidant action and potential antidiabetic properties of an isoflavonoid-containing soyabean phytochemical extract (SPE). Phytother Res 1999;13:601-608.
27. Simoncini T, Fornari L, Mannella P, et al. Activation of nitric oxide synthesis in human endothelial cells by red clover extracts. Menopause 2005;12:69-77.
28. Iglesias Del Sol A, Bots ML, Grobbee DE, Hofman A, Witteman JCM. Carotid intima-media thickness at different sites: Relation to incident myocardial infarction - the Rotterdam Study. Eur Heart J 2002;23:934-940.
29. Bhathena SJ, Velasquez MT. Beneficial role of dietary phytoestrogens in obesity and diabetes. Am J Clin Nutr 2002;76:1191-1201.
30. Shen P, Liu MH, Ng TY, Chan YH, Yong EL. Differential effects of isoflavones, from Astragalus membranaceus and Pueraria thomsonii, on the activation of PPARγ, PPARα, and adipocyte differentiation in vitro. J Nutr 2006;136:899-905.
31. Hwang JT, Park IJ, Shin JI, et al. Genistein, EGCG, and capsaicin inhibit adipocyte differentiation process via activating AMP-activated protein kinase. Biochem Biophys Res Commun 2005;338:694-699.
32. Lakka H-M, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002;288:2709-2716.
33. Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003;107:391-397.
34. Howard BV, Criqui MH, Curb JD, et al. Risk factor clustering in the insulin resistance syndrome and its relationship to cardiovascular disease in postmenopausal White, Black, Hispanic, and Asian/Pacific Islander women. Metabolism 2003;52:362-371.
35. McNeill AM, Rosamond WD, Girman CJ, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005;28:385-390.
36. Guo L, Tabrizchi R. Peroxisome proliferator-activated receptor γ as a drug target in the pathogenesis of insulin resistance. Pharmacol Ther 2006;111:145-173.
37. Staels B. PPARF and atherosclerosis. Curr Med Res Opin 2005;21(Suppl):S13-S20.
38. Kepez A, Oto A, Dagdelen S. Peroxisome proliferator-activated receptor? Novel therapeutic target linking adiposity, insulin resistance, and atherosclerosis. BioDrugs 2006;20:121-135.
39. Panunti B, Fonseca V. Effects of PPAR γ agonists on cardiovascular function in obese, non-diabetic patients. Vasc Pharmacol 2006;45:29-35.
40. Walcher D, Marx N. Insulin resistance and cardiovascular disease: the role of PPARγ activators beyond their anti-diabetic action. Diab Vasc Dis Res 2004;1:76-81.
41. Staels B, Koenig W, Habib A, et al. Activation of human aortic smooth-muscle cells is inhibited by PPAR? but not by PPAR? activators. Nature 1998;393:790-793.
42. Lorenz WW, McCann RO, Longiaru M, Cormier MJ. Isolation and expression of a cDNA encoding Renilla reniformis luciferase. Proc Natl Acad Sci U S A 1991;88:4438-4442.
43. Jungbauer A, Graumann K. The logistic dose-response function: a robust fitting function for transition phenomena in life sciences. J Clin Ligand Assay 2001;24:270-274.
44. Heinonen S-M, Wähälä K, Adlercreutz H. Identification of urinary metabolites of the red clover isoflavones formononetin and biochanin A in human subjects. J Agr Food Chem 2004;52:6802-6809.
45. Yasuda T, Ueda J, Ohsawa K. Urinary metabolites of genistein administered orally to rats. Chem Pharmacol Bull 2001;49:1495-1497.
46. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001;86:280-288.
47. Diamant M, Heine RJ. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 2003;63:1373-1405.
48. Doggrell S. Clinical trials with thiazolidinediones in subjects with type 2 diabetes - is pioglitazone any different from rosiglitazone? Expert Opin Pharmacother 2008;9:405-420.
49. Ghazeeri G, Kutteh WH, Bryer-Ash M, Haas D, Ke RW. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 2003;79:562-566.
50. Unluturk U, Harmanci A, Kocaefe C, Yildiz BO. The genetic basis of the polycystic ovary syndrome: a literature review including discussion of PPAR-γ. PPAR Res 2007;2007:49109.
51. Bryant M, Cassidy A, Hill C, Powell J, Talbot D, Dye L. Effect of consumption of soy isoflavones on behavioural, somatic and affective symptoms in women with premenstrual syndrome. Br J Nutr 2005;93:731-739.
52. Cassidy A, Hanley B, Lamuela-Raventos RM. Isoflavones, lignans and stilbenes - origins, metabolism and potential importance to human health. J Sci Food Agr 2000;80:1044-1062.